Background: There is a lack of scientific consensus about cancer comorbidity in people with central nervous system (CNS) disorders. This study assesses the co-occurrence of cancers in patients with CNS disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), autism spectrum disorders, Down's syndrome (DS), Huntington's disease (HD), multiple sclerosis (MS), Parkinson's disease (PD) and schizophrenia (SCZ). Method: Comprehensive search in PubMed/MEDLINE, Scopus and ISI Web of Knowledge of the literature published before March 2013. We identified 51 relevant articles from 2,229 discrete references, 50 of which contained data suitable for quantitative synthesis (577,013 participants). Pooled effect sizes (ES) were calculated using multiple random-effects meta-analyses. Sources of heterogeneity and uncertainty were explored by means of subgroup and sensitivity analyses, respectively. Results: The presence of CNS disorders was associated with a reduced co-occurrence of cancer (ES = 0.92; 95% confidence interval, CI: 0.87-0.98; I2 = 94.5%). A consistently lower overall co-occurrence of cancer was detected in patients with neurodegenerative disorders (ES = 0.80; 95% CI: 0.75- 0.86; I2 = 82.8%), and in those with AD (ES = 0.32; 95% CI: 0.22-0.46; I2 = 0.0%), PD (ES = 0.83; 95% CI: 0.76-0.91; I2 = 80.0%), MS (ES = 0.91; 95% CI: 0.87-0.95; I2 = 30.3%) and HD (ES = 0.53; 95% CI: 0.42-0.67; I2 = 56.4%). Patients with DS had a higher overall co-occurrence of cancer (ES = 1.46; 95% CI: 1.08-1.96; I2 = 87.9%). No association was observed between cancer and ALS (ES = 0.97; 95% CI: 0.76-1.25; I2 = 0.0%) or SCZ (ES = 0.98; 95% CI: 0.90-1.07; I2 = 96.3%). Patients with PD, MS and SCZ showed (a) higher co-occurrence of some specific cancers (e.g. PD with melanoma, MS with brain cancers and SCZ with breast cancer), and (b) lower co-occurrence of other specific cancers (e.g. lung, prostate and colorectal cancers in PD; lung and prostate cancers in MS; and melanoma and prostate cancer in SCZ). Conclusion: Increased and decreased co-occurrence of cancer in patients with CNS disorders represents an opportunity to discover biological and non-biological connections between these complex disorders.

Keywords:
Comorbidity, Multimorbidity, Cancer, Central nervous system disorders, Alzheimer’s disease, Amyotrophic lateral sclerosis, Autism spectrum disorders, Down’s syndrome, Huntington’s disease, Multiple sclerosis
1.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
2.
Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M: Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009;7:357-363.
3.
Hasle H, Clemmensen IH, Mikkelsen M: Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169.
4.
Catts VS, Catts SV, O'Toole BI, Frost AD: Cancer incidence in patients with schizophrenia and their first-degree relatives: a meta-analysis. Acta Psychiatr Scand 2008;117:323-336.
5.
Bajaj A, Driver JA, Schernhammer ES: Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
6.
Tabarés-Seisdedos R, Dumont N, Baudot A, et al: No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 2011;12:604-608.
7.
Driver JA, Beiser A, Au R, et al: Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012;344:e1442.
8.
Tabarés-Seisdedos R, Gómez-Beneyto M, Haro JM, González-Pinto A, Vieta E: The importance of negative comorbidity. J Clin Psychiatry 2009;70:1191-1192.
9.
Tabarés-Seisdedos R, Rubenstein JL: Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 2009;14:563-589.
10.
Murray CJL, Vos T, Lozano R, et al: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223.
11.
Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
12.
Terret C, Castel-Kremer E, Albrand G, Droz JP: Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol 2009;10:80-87.
13.
Pal SK, Hurria A: Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;10:4086-4093.
14.
Howard LM, Barley EA, Davies E, et al: Cancer diagnosis in people with severe mental illness: practical and ethical issues. Lancet Oncol 2010;11:797-804.
15.
Bercovich D, Ganmore I, Scott LM, et al: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-1492.
16.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
17.
Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ottawa Hospital Research Institute, 2007. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed Sept 15, 2012).
18.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
19.
Cochran WG: The combination of estimates from different experiments. Biometrics 1954;10:101-129.
20.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
21.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
22.
Sterne JAC, Egger M, Moher D: Addressing reporting biases; in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Wiley, 2008, pp 297-334.
23.
Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC: Alzheimer disease and cancer. Neurology 2005;64:895-898.
24.
Roe CM, Fitzpatrick AL, Xiong C, et al: Cancer linked to Alzheimer disease but not vascular dementia. Neurology 2010;74:106-112.
25.
Jansson B, Jankovic J: Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-509.
26.
Møller H, Mellemkjaer L, McLaughlin JK, Olsen JH: Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1501.
27.
Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S: Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000;247:429-434.
28.
Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H: Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
29.
Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK: Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 2005;20:719-725.
30.
Lo RY, Tanner CM, van den Eeden SK, Albers KB, Leimpeter AD, Nelson LM: Comorbid cancer In Parkinson's disease. Mov Disord 2010;25:1809-1817.
31.
Becker C, Brobert GP, Johansson S, Jick SS, Meier CR: Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 2010;16:186-190.
32.
Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ: Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010;81:215-221.
33.
Sun LM, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH: Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. Neuroepidemiology 2011;37:114-119.
34.
Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH: Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer 2012;131:1904-1911.
35.
Bertoni JM, Arlette JP, Fernandez HH, et al: Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010;67:347-352.
36.
Midgard R, Glattre E, Grønning M, Riise T, Edland A, Nyland H: Multiple sclerosis and cancer in Norway: a retrospective cohort study. Acta Neurol Scand 1996;93:411-415.
37.
Sumelahti ML, Pukkala E, Hakama M: Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 2004;23:224-227.
38.
Achiron A, Barak Y, Gail M, et al: Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005;89:265-270.
39.
Nielsen NM, Rostgaard K, Rasmusen S, et al: Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006;118:979-984.
40.
Lebrun C, Debouverie M, Vermersch P, et al: Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008;14:399-405.
41.
Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T: Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009;72:1170-1177.
42.
Kingwell E, Bajdik C, Phillips N, et al: Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 2012;135(pt 10):2973-2979.
43.
Goldacre MJ, Seagroatt V, Yeates D, Acheson ED: Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004;58:142-144.
44.
Zisfein J, Caroscio JT: No association of amyotrophic lateral sclerosis with cancer. Mt Sinai J Med 1988;55:159-161.
45.
Dupont A, Møller Jensen O, Strömgren E, et al: Incidence of cancer in patients diagnosed as schizophrenic in Denmark; in ten Horn GHMM, Giel R, Gulbinat W, et al (eds): Psychiatric Case Registries in Public Health. Amsterdam, Elsevier Science, 1986, pp 229-239.
46.
Gulbinat W, Dupont A, Jablensky A, et al: Cancer incidence of schizophrenic patients: results of record linkage studies in three countries. Br J Psychiatry Suppl 1992;18:75-83.
47.
Lawrence D, Holman CD, Jablensky AV, Threlfall TJ, Fuller SA: Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand 2000;101:382-388.
48.
Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J: Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001;58:573-578.
49.
Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D: Reduced cancer incidence among patients with schizophrenia. Cancer 2005;104:2817-2821.
50.
Grinshpoon A, Barchana M, Ponizovsky A, et al: Cancer in schizophrenia: is the risk higher or lower? Schizophr Res 2005;73:333-341.
51.
Dalton SO, Mellemkjaer L, Thomassen L, Mortensen PB, Johansen C: Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res 2005;75:315-324.
52.
Goldacre MJ, Kurina LM, Wotton CJ, Yeates D, Seagroat V: Schizophrenia and cancer: an epidemiological study. Br J Psychiatry 2005;187:334-338.
53.
Chou FH, Tsai KY, Su CY, Lee CC: The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res 2011;129:97-103.
54.
Lin GM, Chen YJ, Kuo DJ, et al: Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997-2009. Schizophr Bull 2013;39:407-416.
55.
Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X: Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull 2013;39:527-536.
56.
McGinty EE, Zhang Y, Guallar E, et al: Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv 2012;63:714-717.
57.
Kisely S, Crowe E, Lawrence D: Cancer-related mortality in people with mental illness. JAMA Psychiatry 2013;70:209-217.
58.
Crump C, Winkleby MA, Sundquist K, Sundquist J: Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324-333.
59.
Lin CY, Lane HY, Chen TT, Wu YH, Wu CY, Wu VY: Inverse association between cancer risks and age in schizophrenia patients: a 12-year nationwide cohort study. Cancer Sci 2013;104:383-390.
60.
Osborn DP, Limburg H, Walters K, et al: Relative incidence of common cancers in people with severe mental illness: cohort study in the United Kingdom THIN primary care database. Schizophr Res 2013;143:44-49.
61.
Dalton SO, Munk Laursen T, Mellemkjaer L, Johansen C, Mortensen PB: Schizophrenia and the risk for breast cancer. Schizophr Res 2003;62:89-92.
62.
Hippisley-Cox J, Vinogradova Y, Coupland C, Parker C: Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry 2007;64:1368-1376.
63.
Barak Y, Levy T, Achiron A, Aizenberg D: Breast cancer in women suffering from serious mental illness. Schizophr Res 2008;102:249-253.
64.
Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D: Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004;89:1014-1017.
65.
Boker LK, Blumstein T, Sadetzki S, et al: Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int J Cancer 2001;93:741-744.
66.
Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M: Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer 2006;118:1769-1772.
67.
Sullivan SG, Hussain R, Glasson EJ, Bittles AH: The profile and incidence of cancer in Down syndrome. J Intellect Disabil Res 2007;51(pt 3):228-231.
68.
Bjørge T, Cnattingius S, Lie RT, Tretli S, Engeland A: Cancer risk in children with birth defects and in their families: a population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev 2008;17:500-506.
69.
Sørensen SA, Fenger K, Olsen JH: Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 1999;86:1342-1346.
70.
Ji J, Sundquist K, Sundquist J: Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 2012;13:642-648.
71.
Lauritsen MB, Mors O, Mortensen PB, Ewald H: Medical disorders among inpatients with autism in Denmark according to ICD-8: a nationwide register-based study. J Autism Dev Disord 2002;32:115-119.
72.
Sirri L, Fava GA, Sonino N: The unifying concept of illness behavior. Psychother Psychosom 2013;82:74-81.
73.
Tabarés-Seisdedos R, Rubenstein JL: Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci 2013;14:293-304.
74.
Devine MJ, Plun-Favreau H, Wood NW: Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer 2011;11:812-823.
75.
Handel AE, Ramagopalan SV: GPC5 and lung cancer in multiple sclerosis. Lancet 2010;11:714.
76.
Nižetić D, Groet J: Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer 2012;12:721-732.
77.
Goriely A, McGrath JJ, Hultman CM, Wilkie AO, Malaspina D: ‘Selfish spermatogonial selection': a novel mechanism for the association between advanced paternal age and neurodevelopmental disorders. Am J Psychiatry 2013;170:599-608.
78.
Ondicova K, Mravec B: Role of nervous system in cancer aetiopathogenesis. Lancet Oncol 2010;11:596-601.
79.
Jemal A: Global burden of cancer: opportunities for prevention. Lancet 2012;380:1797-1799.
80.
Emanuel E: Prevention and cost control. Science 2012;337:1433.
81.
Greenland S: Can meta-analysis be salvaged? Am J Epidemiol 1994;140:783-787.
82.
Catalá-López F, Gènova-Maleras R, Vieta E, Tabarés-Seisdedos R: The increasing burden of mental and neurological disorders. Eur Neuropsychopharmacol 2013;23:1337-1339.
83.
Østergaard SD, Petrides G, Dinesen PT, Skadhede S, Bech P, Munk-Jørgensen P, Nielsen J: The association between physical morbidity and subtypes of severe depression. Psychother Psychosom 2013;82:45-52.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.